News

A promising career as a securities lawyer awaited Doug Branch when he graduated from the University of Oklahoma College of Law in 1982. Oklahoma was the heart of a booming energy economy with lots of oil and gas firms that needed legal work as they raised capital and dealt with regulators.

It’s a rare moment that the leaders and scientists of Oklahoma’s bioscience industry can come together to share the collaborative spirit that is such a part of who they are and what they are creating. The annual OKBIO Summit and BioScience Awards dinner is one of those moments.

An Emerging Tech Center: Oklahoma City notable home-grown startups in Innovation Magazine Copyright © 2016 | Innovation America Accele BioPharma (founded in 2011) — Biotechnology business accelerator located in the University Research Park, formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking early stage life science technologies. http://accelebio.com Analytical Research Laboratories/DNA Solutions/The KupiecRead more

Oklahoma City has hit its share of biotech home runs.

Alexion, the biotech giant with a market capitalization of almost $40 billion, grew out of discoveries made at the Oklahoma Medical Research Foundation. Likewise, work at the University of Oklahoma Health Sciences Center gave birth to Novazyme Pharmaceuticals, which Genzyme purchased for more than $200 million in 2001. And Myriad Genetics acquired OMRF spin-off Crescendo Biosciences in 2014 for $270 million.

In Oklahoma City, Entrepreneurs Aim to Create the Next Cool Startup Scene By Anna Hensel, Inc.com For U.S. cities looking to become the next big tech hub, it’s not enough to just recruit eager entrepreneurs. Cities also have to attract the employees (coders, designers, salespeople) who can keep the startup afloat. A fine example of oneRead more

Foreign investment in Oklahoma should help the state’s biotech industry expand, said patent attorney Mike LaBrie.

Cytovance Biologics Inc., an Oklahoma City-based pharmaceutical contract manufacturer, will be acquired by a unit of a Chinese company in a $206 million deal, the companies announced Monday.

Monroe Capital said it acted as sole lead arranger and administrative agent on the funding of a $20 million senior credit facility for Cytovance Biologics Inc., by private equity sponsor, Great Point Partners.

The 2014 Biotechnology Industry Organization convention is a whirlwind of potential success for Darren Head, president and CEO of Oklahoma City-based Cytovance Biologics Inc.

A pair of Oklahoma City-based companies have been selected as “Buzz of BIO” nominees for the 2014 Biotechnology Industry Organization annual convention.

Founded in 2003 by former executives of Novazyme Pharmaceuticals, Cytovance delivers a broad menu of specialized contract biological manufacturing services that help companies such as Oklahoma City’s Selexys Pharmaceuticals manufacture drugs for clinical trials.

Cytovance Biologics Inc. has an agreement with Selexys Pharmaceuticals Corp. to produce the SelG1 monoclonal antibody for a clinical study.